Here is why my valuation of IPIX differs so greatly from others:
What would you have said the value of IPIX was in Dec 2019?
At that time we had B targeted ONLY for the GI tract (I consider OM and UC,Crohn's, UP, and USP all part of GI tract) and ABSSSI.
We knew it had great potential for dermatology and respiratory indications but due to financial reasons they hadn't, and to date still haven't, been addressed.
All of a sudden 2020 starts and we find that Brilacidin could set the world of virology on its ear and become the greatest virus killer across the ENTIRE spectrum of viruses for both treatment and recently throw in vaccines as well (though this hasn't been developed yet but indications lead many to believe it would work wonders as a vaccine). And it looks like it could become extremely important as a drug for kidney indications, brain swelling, COPD, bronchitis, asthma, ear drops, etc. Delivery systems could include IV, pill, nasal spray, and nebulizer.
The whole dynamic of Brilacidin changed in 2020 as did the financial expectations for IPIX.
And yet we still haven't but scratched the surface of Brilacidin's full possibilities as we also have fungal, biofilms, and the whole world of industrial uses via changing it from a small molecule to a polymer (just a string of B molecules linked together) which could be used in paints, plastics, textiles, bandages, catheters, and lord knows how many other uses.
I believe Humira is the largest selling drug currently at about $14B/yr or so and IMO Brilacidin has the possibility of surpassing it. I know this is a very long term view but it has the possibility.
Kevetrin is another humongous drug possibility in itself and is only lacking a small amount of funds to complete toxilogical testing of the pill formulation for it to be used in probably a boat load of trials as a complementary drug for EVERY current cancer treatment being used today in addition to working as a stand alone treatment.
As you can see from above, my numbers are very high and I won't go into any further detail as to the amount I see for the Brilacidin platform as IMO it must be given to a single BP since with the many delivery systems and the spectrum of indications on which it will work how could you give a patient an ABSSSI IV and not expect it to also help conditions in the brain, lungs, GI tract, etc? Too many overlapping possibilities so that many, many lawsuits by our partners would ensue IMO.
Assume B was sold for $50/share to some BP, that would bring in (assuming 400MM shares for a nice round number) $20B to IPIX. From what I see Brilacidin doing down the road, that could be about 1-2 years revenues. Great deal for the BP, not so much for IPIX considering a BP hasn't done jack squat in assuming any risk or putting up the money when it was needed by IPIX.
But the largest ? at this time is how many further MAJOR revenue streams will Brilacidin address and most likely become the leading treatment? How large will Kevetrin become? What will 2021 bring and 2022 as to new giant opportunities for our drugs? IPIX is going to be swimming in money soon IMO, no need to jump on a partnership right away and certainly no time to be considering a buyout.
